Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study
Authors:
Open Access
- 17 September 2020
- journal article
- research article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 20 (1) , 1-10
Abstract
Background: We previously showed that the 10-year cardiovascular disease (CVD) risk threshold to initiate statins for primary prevention depends on the baseline CVD risk, age, sex, and the incidence of statin-related harm outcome and competing risk for non-CVD death. As these factors appear to vary across countries, we aimed in this study to determine country-specific thresholds and provide guidelines a quantitative benefit-harm assessment method for local adaptation.Methods: For each of the 186 countries included, we replicated the benefit-harm balance analysis using an exponential model to determine the thresholds to initiate statin use for populations aged 40 to 75 years, with no history of CVD. The analyses took data inputs from a priori studies, including statin effect estimates (network meta-analysis), patient preferences (survey), and baseline incidence of harm outcomes and competing risk for non-CVD (global burden of disease study). We estimated the risk thresholds above which the benefits of statins were more likely to outweigh the harms using a stochastic approach to account for statistical uncertainty of the input parameters.Results: The 5thand 95thpercentiles of the 10-year risk thresholds above which the benefits of statins outweigh the harms across 186 countries ranged between 14 and 20% in men and 19–24% in women, depending on age (i.e., 90% of the country-specific thresholds were in the ranges stated). The median risk thresholds varied from 14 to 18.5% in men and 19 to 22% in women. The between-country variability of the thresholds was slightly attenuated when further adjusted for age resulting, for example, in a 5thand 95thpercentiles of 14–16% for ages 40–44 years and 17–21% for ages 70–74 years in men. Some countries, especially the islands of the Western Pacific Region, had higher thresholds to achieve net benefit of statins at 25–36% 10-year CVD risks.Conclusions: This extensive benefit-harm analysis modeling shows that a single CVD risk threshold, irrespective of age, sex and country, is not appropriate to initiate statin use globally. Instead, countries need to carefully determine thresholds, considering the national or subnational contexts, to optimize benefits of statins while minimizing related harms and economic burden.Keywords
Funding Information
- Swiss Excellence Scholarship (2015.0858)
- North-South Cooperation, University of Zurich (F-42320–71–01)
- Béatrice Ederer-Weber Foundation
This publication has 28 references indexed in Scilit:
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsJACC, 2014
- Comparative Tolerability and Harms of Individual StatinsCirculation: Cardiovascular Quality and Outcomes, 2013
- Comparative effects of statins on major cerebrovascular events: a multiple-treatments meta-analysis of placebo-controlled and active-comparator trialsQJM: An International Journal of Medicine, 2013
- Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010The Lancet, 2012
- Statins and risk of treated incident diabetes in a primary care populationBritish Journal of Clinical Pharmacology, 2012
- Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorialJournal of Clinical Epidemiology, 2011
- Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk ScoreEuropean Heart Journal, 2010
- Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch databaseBMJ, 2010
- Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trialsBritish Journal of Clinical Pharmacology, 2008
- World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countriesJournal Of Hypertension, 2007